Trial Profile
Efficacy of ceftazidime-avibactam CAZ-AVI) in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing: A retrospecitve study
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 10 Jul 2018
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Klebsiella infections
- Focus Expanded access; Therapeutic Use
- 10 Jul 2018 New trial record
- 09 Jun 2018 Results published in the Clinical Infectious Diseases